Clinical Trials in Atlanta

Showing 2921-2940 of 9,468 trials

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

NCT01197378

Cystinosis is an inherited disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate immediate release) which must be taken every six hours for the rest of the patient's life to prevent complications of cystinosis. Cysteamine bitartrate delayed-release capsules (RP103) is a formulation of cysteamine bitartrate that is being studied to see if it can be given less frequently, once every 12 hours, and have similar results to four times a day Cystagon®.

Cystinosis

Amgen60 participantsStarted Aug 2010

San Francisco, California, United States • Stanford, California, United States • Atlanta, Georgia, United States +7 more locations

Active Not RecruitingNA< 1 mile

Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication

NCT04252573

Prospective, multi-center, non-randomized study with consecutive, eligible subject enrollment at each site, for the evaluation of the ChEVAS System for Endovascular Repair of Complex Abdominal Aortic Aneurysms.

1 Paravisceral Abdominal Aortic Aneurysm2 Juxtarenal Abdominal Aortic Aneurysm3 Pararenal Abdominal Aortic Aneurysm+1 more

Endologix13 participantsStarted Jun 2020

Huntsville, Alabama, United States • Washington D.C., District of Columbia, United States • Atlanta, Georgia, United States +5 more locations

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication

Find Trials by Condition in Atlanta

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Endovascular Engineering ENGULF Study

Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

A Drug-drug Interaction Study of Avapritinib and Midazolam

CYPRESS Efficacy and Safety Study Extension

Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers

Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)

Nitrous Oxide for the Treatment of Major Depressive Disorder

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma